Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL)
USD 25.04
(-1.14%)
USD 25.04
(-1.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.72 Million USD | 573.27% |
| 2022 | -3.2 Million USD | -9.14% |
| 2021 | -10.14 Million USD | 90.1% |
| 2020 | 3.49 Million USD | -48.56% |
| 2019 | 1.43 Million USD | 172.46% |
| 2018 | -2.73 Million USD | 79.97% |
| 2017 | -10.39 Million USD | -26.24% |
| 2016 | -14.05 Million USD | 17.03% |
| 2015 | -14.21 Million USD | -41.71% |
| 2014 | -10.06 Million USD | -31.31% |
| 2013 | -7.63 Million USD | -83.57% |
| 2012 | -5.35 Million USD | -343.13% |
| 2011 | -878.59 Thousand USD | 62.46% |
| 2010 | -2.47 Million USD | 45.19% |
| 2009 | -4.55 Million USD | -10.73% |
| 2008 | -4.12 Million USD | -49.95% |
| 2007 | -2.74 Million USD | -5847.39% |
| 2006 | -46.2 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.73 Million USD | 157.4% |
| 2024 Q1 | -3.74 Million USD | -196.54% |
| 2023 Q1 | 1.21 Million USD | 168.05% |
| 2023 Q2 | 2.35 Million USD | 94.38% |
| 2023 Q4 | -1.61 Million USD | -192.43% |
| 2023 FY | - USD | 573.27% |
| 2023 Q3 | 1.74 Million USD | -25.85% |
| 2022 Q3 | -2.78 Million USD | -55720.0% |
| 2022 Q4 | -1.77 Million USD | 36.07% |
| 2022 Q1 | 162 Thousand USD | 112.89% |
| 2022 Q2 | 5000.00 USD | -96.91% |
| 2022 FY | - USD | -9.14% |
| 2021 FY | - USD | 90.1% |
| 2021 Q2 | 3.77 Million USD | 745.81% |
| 2021 Q1 | -585 Thousand USD | -122.28% |
| 2021 Q3 | -3.85 Million USD | -202.12% |
| 2021 Q4 | -1.25 Million USD | 67.42% |
| 2020 Q4 | 2.62 Million USD | 108.74% |
| 2020 FY | - USD | -48.56% |
| 2020 Q2 | -3.43 Million USD | -303.88% |
| 2020 Q1 | -851 Thousand USD | 40.28% |
| 2020 Q3 | 1.25 Million USD | 136.6% |
| 2019 Q1 | 26 Thousand USD | -99.35% |
| 2019 FY | - USD | 172.46% |
| 2019 Q2 | -1.61 Million USD | -6296.15% |
| 2019 Q3 | 9.78 Million USD | 707.64% |
| 2019 Q4 | -1.42 Million USD | -114.56% |
| 2018 Q2 | -5.48 Million USD | -314.98% |
| 2018 Q1 | -1.32 Million USD | 20.89% |
| 2018 FY | - USD | 79.97% |
| 2018 Q4 | 3.99 Million USD | 2491.62% |
| 2018 Q3 | -167 Thousand USD | 96.96% |
| 2017 Q2 | -8.06 Million USD | -113.38% |
| 2017 Q1 | -3.78 Million USD | -244.67% |
| 2017 Q4 | -1.67 Million USD | -22.42% |
| 2017 Q3 | -1.36 Million USD | 83.08% |
| 2017 FY | - USD | -26.24% |
| 2016 Q3 | -3.57 Million USD | 1.89% |
| 2016 Q2 | -3.64 Million USD | -5.22% |
| 2016 Q1 | -3.46 Million USD | 23.55% |
| 2016 Q4 | -1.09 Million USD | 69.35% |
| 2016 FY | - USD | 17.03% |
| 2015 Q3 | -3.35 Million USD | -0.84% |
| 2015 FY | - USD | -41.71% |
| 2015 Q4 | -4.53 Million USD | -35.09% |
| 2015 Q2 | -3.32 Million USD | -11.3% |
| 2015 Q1 | -2.99 Million USD | -10.39% |
| 2014 FY | - USD | -31.31% |
| 2014 Q1 | -2.32 Million USD | -23.55% |
| 2014 Q2 | -2.56 Million USD | -10.6% |
| 2014 Q3 | -2.42 Million USD | 5.48% |
| 2014 Q4 | -2.7 Million USD | -11.59% |
| 2013 Q4 | -1.87 Million USD | 9.45% |
| 2013 Q3 | -2.07 Million USD | 6.35% |
| 2013 Q2 | -2.21 Million USD | -51.37% |
| 2013 Q1 | -1.46 Million USD | -0.85% |
| 2013 FY | - USD | -83.57% |
| 2012 Q4 | -1.45 Million USD | -16.64% |
| 2012 Q1 | -351.51 Thousand USD | -12.25% |
| 2012 Q2 | -1.11 Million USD | -216.3% |
| 2012 Q3 | -1.24 Million USD | -11.97% |
| 2012 FY | - USD | -343.13% |
| 2011 Q3 | -66.49 Thousand USD | 54.36% |
| 2011 FY | - USD | 62.46% |
| 2011 Q2 | -145.69 Thousand USD | 64.77% |
| 2011 Q1 | -413.55 Thousand USD | -8.77% |
| 2011 Q4 | -313.14 Thousand USD | -370.92% |
| 2010 Q1 | -870.48 Thousand USD | -12.14% |
| 2010 FY | - USD | 45.19% |
| 2010 Q2 | -522.79 Thousand USD | 39.94% |
| 2010 Q4 | -380.2 Thousand USD | 47.74% |
| 2010 Q3 | -727.5 Thousand USD | -39.16% |
| 2009 Q2 | -1.23 Million USD | 24.43% |
| 2009 FY | - USD | -10.73% |
| 2009 Q4 | -776.25 Thousand USD | 16.44% |
| 2009 Q3 | -928.97 Thousand USD | 24.48% |
| 2009 Q1 | -1.62 Million USD | -68.79% |
| 2008 Q2 | -1.28 Million USD | -22.89% |
| 2008 Q3 | 834.67 Thousand USD | 165.19% |
| 2008 Q4 | -964.35 Thousand USD | -215.54% |
| 2008 FY | - USD | -49.95% |
| 2008 Q1 | -1.04 Million USD | 32.94% |
| 2007 FY | - USD | -5847.39% |
| 2007 Q3 | 969.14 Thousand USD | 87489.0% |
| 2007 Q1 | -1897.00 USD | 34.65% |
| 2007 Q2 | -1109.00 USD | 41.54% |
| 2007 Q4 | -1.55 Million USD | -260.33% |
| 2006 Q4 | -2903.00 USD | 62.46% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | -7733.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -22.13 Million USD | 143.928% |
| BIMI International Medical Inc. | -15.33 Million USD | 163.39% |
| China Jo-Jo Drugstores, Inc. | 1.22 Million USD | -692.521% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 9.72 Million USD | 0.0% |
| Leafly Holdings, Inc. | -5.73 Million USD | 269.567% |
| Leafly Holdings, Inc. | -5.73 Million USD | 269.567% |
| LifeMD, Inc. | -8.21 Million USD | 218.368% |
| LifeMD, Inc. | -8.21 Million USD | 218.368% |
| TRxADE HEALTH, Inc. | -13.72 Million USD | 170.865% |
| PetMed Express, Inc. | -394 Thousand USD | 2567.766% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 100.086% |